KHTRF News and Press, Knight Therapeutics Inc

MONTREAL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian he...

2026-01-05 16:10:00 ET From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic. Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies su...

MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved  WYNZORA ® , a white uniform cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 mg...

2025-11-06 17:46:14 ET Knight Therapeutics Inc. (GUD:CA) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST... Read the full article on Seeking Alpha For further details see: Knight Therapeutics Inc. (GUD:CA) Q3 2025 Earnings Call Transcript

2025-11-06 08:25:56 ET More on Knight Therapeutics Inc. Seeking Alpha’s Quant Rating on Knight Therapeutics Inc. Historical earnings data for Knight Therapeutics Inc. Financial information for Knight Therapeutics Inc. Read the full article on Seeking...

Achieved record-high quarterly revenues, Adjusted EBITDA 1 and Adjusted EBITDA per share 1 since inception Increased 2025 financial guidance MONTREAL, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or ...

2025-11-05 18:00:33 ET Major earnings expected before the bell on Thursday include: Viatris ( VTRS ) Moderna ( MRNA ) ConocoPhillips ( COP ) Datadog ( DDOG ) AstraZeneca PLC ( AZN ) Read the full article on Seeking Alpha For further de...

MONTREAL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has closed the syndication of its US$100 million secured revolving credit facility (“t...

2025-10-30 17:39:17 ET More on Knight Therapeutics Inc. Knight Therapeutics Inc. (KHTRF) Q2 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on Knight Therapeutics Inc. Historical earnings data for Knight Therapeutics Inc. Financial informati...

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of JORNAY PM™ (methylphenidate HCI extended-release capsules) in Canada. JORNAY PM™ is an extended-release...